CTRI/2009/091/001073招募中4 期
TO EVALUATE THE EFFICACY AND SAFETY OF FIXED DOSE 1.5 % AMINEXIL AND 5 % MINOXIDIL TOPICAL SOLUTION V/S 5 % MINOXIDIL TOPICAL SOLUTION IN MALE PATTERN HAIR LOSS.
Glenmark Pharmaceuticals Ltd0 个研究点目标入组 204 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 204
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male patients of age between 18 to 50.
- •2. Presence of androgenetic alopecia based on the Norwood Hamilton Scale grade 3 and 4 with
- •vertex involvement (Appendix B).
- •3. Accepting not to use products with the same end benefit during the entire study duration.
- •4. For whom the Investigator considers that the compliance will be correct.
- •5. Cooperating, informed of the need and duration of the examinations, and ready to comply with
- •protocol procedures.
- •6. Having signed a Consent Form and will be once informed orally and in writing of all information
- •concerning the study procedures and study objectives.
排除标准
- •1. Alopecia areata, alopecia totalis, alopecia universalis and alopecia diffusa.
- •2. Scarring of the scalp or any other condition or disease of the scalp or hair, including diseases of
- •the hair shaft and inability to discontinue use of hair weaving.
- •3. Volunteers with any cardiac abnormalities or ailments or abnormal blood pressure.
- •4. Use of the following during the 6 months prior to screening:
- •? Minoxidil (oral or topical)
- •? Drugs with anti-androgenic properties (e.g., cyproterone acetate, spironolactone,
- •ketoconazole, flutamide, bicalutamide). Cimetidine cannot be used during the study but is not
- •an excluded drug when used during the previous 6 months.
- •? Drugs potentially causing hypertrichosis (e.g., cyclosporine, diazoxide, phenytoin psoralens)
- •? Anabolic steroids
- •? Lithium and phenothiazines.
- •5. Use of systemic steroids for more than 14 days within the past 2 months prior to enrollment in
- •6. Use of isotretinoin, radiation to the scalp, or chemotherapy within the past year.
- •7. Known sensitivity to the investigational product.
- •8. Hypersensitivity to any cosmetic product, raw material.
- •9. Any clinically significant systemic or cutaneous disease, which may interfere with study
- •treatments or procedures.
- •10. Subjects on any medical treatment either systemic or topical which may interfere with the
- •performance of the study treatment (presently or in the past 1 month).
- •11. Subject in an exclusion period or participating in another similar cosmetic or therapeutic trial.
研究者
相似试验
已完成
4 期
A Clinical Study to observe the effects of combination of Telmisartan and Amelodipine in patients with Uncontrolled Hypertension alone,Or with Type II Diabetes MellitusCTRI/2011/12/002189Glenmark Pharmaceuticals Ltd1,000
已完成
4 期
A clinical trial to study the effects of two drugs Olmesartan and metoprolol in patients with high blood pressure and heart diseaseCTRI/2010/091/001438Glenmark Pharmaceuticals Limited1,000
招募中
4 期
A Clinical Study to Evaluate the Safety and Efficacy of fixed dose combination of L-Ornithine-L-Aspartate 150 mg, Pancreatin IP 100mg enteric coated tablets as supportive and maintenance therapy in hepatitisCTRI/2022/06/043453Win Medicare Pvt Ltd
已完成
3 期
A clinical trial to study the efficacy and safety of fixed dose combination of a proton pump inhibitor and a dopamine antagonist in the treatment of gastroesophageal reflux disease.CTRI/2012/03/002508Sun Pharmaceutical Industries Ltd200
尚未招募
3 期
A clinical trial to study the efficacy and safety of fixed dose combination in the treatment of gastroesophageal reflux disease.CTRI/2012/04/002575Sun Pharmaceutical Industries Ltd200